The Senate Judiciary Committee passed a parcel of legislation on June 27 that backers hope will help rein in drug prices.

The mark-up was just the latest in a series of legislative, regulatory and litigative steps that have every party along the drug industry’s supply chain on their heels. Divided on many other  issues, the committee members coalesced around the problem.

The four bills were the Prescription Pricing for the People Act (S. 1227), the PACED Act (S. 440), the Stop STALLING Act (S. 1224), and the Affordable Prescriptions for Patients Act (S. 1416).

The Prescription Pricing bill requires the FTC to study how pharmacy benefits managers affect the costs of drugs. The PACED Act bans the practice of hiding drug patents with native tribes to assert “sovereign immunity.” The Stop STALLING Ac, takes aim at “sham” citizen petitions by drugmakers. The Affordable Prescriptions act would give the FTC jurisdiction over “anticompetitive” behavior by drugmakers.